Insulinoma is the most common pancreatic endocrine tumor. Localization of small tumors remains a diagnostic challenge. Recently, Mangafodipir-enhanced MR imaging using a whole-body coil has been shown to be effective in the detection and staging of pancreatic cancer [3]. Localization of even small tumors is improved and surgical techniques, such as robotic-assisted surgery, have been made possible.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-003-2017-2DOI Listing

Publication Analysis

Top Keywords

localization small
8
small tumors
8
mangan-enhanced imaging
4
imaging detection
4
detection localisation
4
localisation small
4
small pancreatic
4
pancreatic insulinoma
4
insulinoma insulinoma
4
insulinoma common
4

Similar Publications

Habitat fragmentation increases the risk of local extinction of small reptiles: A case study on Phrynocephalus przewalskii.

Ecotoxicol Environ Saf

January 2025

Gansu Key Laboratory of Biomonitoring and Bioremediation for Environmental Pollution, School of Life Sciences, Lanzhou University, Lanzhou 730000, China. Electronic address:

Habitat fragmentation represents a multifaceted global conservation threat, exerting both direct and indirect effects on individual animals and communities. Reptiles, particularly smaller species with limited migratory abilities, are especially vulnerable to these changes. This study examines how small reptiles adapt their life history strategies in fragmented habitats and determines whether their responses are primarily due to phenotypic plasticity or genetic adaptation.

View Article and Find Full Text PDF

Background: Nirmatrelvir with ritonavir (Paxlovid) is indicated for patients with Coronavirus Disease 2019 (COVID-19) who are at risk for progression to severe disease due to the presence of one or more risk factors. Millions of treatment courses have been prescribed in the United States alone. Paxlovid was highly effective at preventing hospitalization and death in clinical trials.

View Article and Find Full Text PDF

Background: Chronic active Epstein-Barr virus (CAEBV) infection is a rare disease in which the Epstein-Barr virus (EBV) persists and replicates, causing chronic symptoms and fatal complications. The treatment of CAEBV is still evolving. Our case report showed a new therapy for CAEBV.

View Article and Find Full Text PDF

Direct-acting antiviral (DAA) therapy is associated with a significant reduction in hepatocellular carcinoma (HCC) incidence among patients with cirrhosis, but data are conflicting about the risk of recurrence following DAA therapy. DAA-PASS was a prospective, pragmatic, observational study designed to estimate the risk of HCC recurrence associated with DAA therapy exposure during routine clinical care. Eligible patients were DAA treatment naive with Barcelona Clinic Liver Cancer (BCLC) stage A.

View Article and Find Full Text PDF

Thrombolysis for aneurysmal subarachnoid haemorrhage.

Cochrane Database Syst Rev

January 2025

Ageing Clinical and Experimental Research, University of Aberdeen, Aberdeen, UK.

Background: Aneurysmal subarachnoid haemorrhage continues to cause a significant burden of morbidity and mortality despite advances in care. Trials investigating local administration of thrombolytics have reported promising results.

Objectives: - To assess the effect of thrombolysis on improving functional outcome and case fatality following aneurysmal subarachnoid haemorrhage - To determine the effect of thrombolysis on the risk of cerebral artery vasospasm, delayed cerebral ischaemia, and hydrocephalus following subarachnoid haemorrhage - To determine the risk of complications of local thrombolysis in aneurysmal subarachnoid haemorrhage SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (last searched 9 March 2023), MEDLINE Ovid (1946 to 9 March 2023), and Embase Ovid (1974 to 9 March 2023).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!